NRXP logo

NRX PHARMACEUTICALS INC

NRXPNASDAQ
🏆 #3994 by market capUS Equity
$630.67▲ $2.84 (+0.45%)
Simulated price
🔔
Track NRXP
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 0.5%
7d▲ 18839.0%
14d▲ 18394.7%
30d▲ 17715.5%
ytd▲ 23345.0%
1y▲ 19305.2%
🏦Market Cap
$124M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
46.6%
Healthy
💵FCF Margin
—
⚖️P/S Ratio
38.1x
Expensive
Otter Score
72
Fair

Trading Snapshot

Day Range
$626.79 – $634.66
52-Week Range
$1.62 – $5.06
Volume
$3.22B
Avg Volume
$2.23B
Shares Outstanding
36.2M
Next Earnings
Oct 26, 2026

Fundamentals Snapshot

Annual Revenue
$3M
Last Q Revenue
$765,780
P/E Ratio
—
P/S Ratio
38.1x
EPS (TTM)
$-0.74
Dividend Yield
—
Dilution (1yr)
+201.7%

Why Investors Own NRXP

  • ✓High-growth profile — revenue up +27.6% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 73% gross margin and 7% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

NRXP logo

NRX PHARMACEUTICALS INC

NRXP
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$1M▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$16M▼ −17.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$14M▲ +32.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
31.7M▲ +201.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$7M▲ +$12M YoY
StockOtter · stockotter.space

About NRX PHARMACEUTICALS INC

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
72/100

Analyst Price Target

ⓘ
Average Target
$836.01
▲ +32.6% Upside
High Target$959.43
Low Target$724.05
Based on 36 analysts

Latest News & Updates

🚀
Reuters·2h ago

NRX PHARMACEUTICALS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift NRXP price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

NRX PHARMACEUTICALS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.